Leerink Partnrs Has Positive Outlook of ZNTL FY2024 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Investment analysts at Leerink Partnrs lifted their FY2024 EPS estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($2.68) per share for the year, up from their previous forecast of ($3.05). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.76) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($1.01) EPS, FY2025 earnings at ($3.47) EPS, FY2026 earnings at ($3.39) EPS and FY2027 earnings at ($3.14) EPS.

Other equities analysts also recently issued reports about the company. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price on the stock in a research report on Monday, August 12th. Guggenheim cut their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. Oppenheimer reissued an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Zentalis Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ ZNTL opened at $2.99 on Monday. Zentalis Pharmaceuticals has a 12-month low of $2.66 and a 12-month high of $18.07. The firm has a market capitalization of $213.08 million, a price-to-earnings ratio of -1.20 and a beta of 1.74. The firm has a 50 day moving average of $3.42 and a 200 day moving average of $5.26.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ZNTL. GSA Capital Partners LLP grew its holdings in shares of Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after purchasing an additional 353,384 shares during the last quarter. Decheng Capital LLC increased its position in shares of Zentalis Pharmaceuticals by 46.2% during the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after acquiring an additional 970,859 shares during the period. XTX Topco Ltd raised its stake in shares of Zentalis Pharmaceuticals by 1,581.9% during the second quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock valued at $730,000 after acquiring an additional 167,854 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after purchasing an additional 585,644 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after purchasing an additional 399,745 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.